12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Invocana canagliflozin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Jan. 10, 2013, to discuss an NDA from Johnson & Johnson for Invocana canagliflozin to treat Type II diabetes....

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >